LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer

Molecular Carcinogenesis

Volumn 52, Issue 8, 2013, Pages 660-665

  Tigli, Hatice ^a   Seven, Didem ^a   Tunc, Murat ^a   Sanli, Oner ^a   Basaran, Serife ^b   Ulutin, Turgut ^a   Buyru, Nur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Bladder cancer; LKB1; MTOR pathway; Mutation; Rheb

Indexed keywords

IMATINIB; PROTEIN KINASE LKB1; RHEB PROTEIN;

ARTICLE; BLADDER; BLADDER CANCER; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON;

BLADDER CANCER; LKB1; MTOR PATHWAY; MUTATION; RHEB;

BASE SEQUENCE; CODON; DISEASE PROGRESSION; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; INTRONS; MONOMERIC GTP-BINDING PROTEINS; NEUROPEPTIDES; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 84880328115     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21902     Document Type: Article

References (53)

1. Jensen OM, Estève J, Møller J, Renard H. Cancer in the European community and its member states. Eur J Cancer 1990; 26: 1167-1177.
2. Franekova M, Halasova E, Bukovska E, Luptak J, Dobrota D. Gene polymorphisms in bladder cancer. Urol Oncol 2008; 26: 1-8.
3. Zaravinos A, Lambrou GI, Volanis D, Delakas D, Spandidos DA. Spotlight on differentially expressed genes in urinary bladder cancer. PLoS ONE 2011; 6: e18255.
4. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16: 3215-3216.
5. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80: 904-908.
6. Lopez- Knowles E, Hernamdez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006; 66: 7401-7404.
7. Knowles MA, Habuchi T, Kennedy W, Cuthbert- Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003; 63: 7652-7656.
8. Chow NH, Chan SH, Tzai TS, Ho Cl, Liu Hs. Expression profiles of Erb3 family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7: 1957-1962.
9. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24: 5218-5225.
10. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
11. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
12. Bjornsti MA, Houghton PJ. Lost in translation: Dysregulation of cap-dependent regulation and cancer. Cancer Cell 2004; 5: 519-523.
13. Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: Partners in development and tumorigenesis. Cell Cycle 2007; 66: 2902-2905.
14. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the plekstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439-444.
15. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430.
16. Eng C. PTEN: One gene, many syndromes. Hum Mutat 2003; 22: 183-198.
17. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18: 77-82.
18. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: Mutations in a signalling pathway. Nature 2005; 436: 792.
19. Shorning BY, Griffiths D, Clarke AR. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS ONE 2011; 6: e16209.
20. Chen RW, Avizienyte E, Roth S, et al. PTEN and LKB1 genes in laryngeal tumours. J Med Genet 1999; 36: 943-944.
21. Hemminki A, Avizienyte E, Roth S, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-187.
22. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine/threonine kinase. Nat Genet 1998; 18: 38-43.
23. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004; 18: 1533-1538.
24. Lizcano JM, Göransson O, Toth R, et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004; 23: 833-843.
25. Alessi DR, Sakamoto K, Bayaskas JR. LKB1-dependent signalling pathways. Annu Rev Biochem 2006; 75: 137-163.
26. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-590.
27. Basso AD, Mirza A, Liu G, Long BJ, Bishop WR, Kirschmeier P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. J Biol Chem 2005; 280: 31101-31108.
28. Platt FM, Hurst CD, Taylor CF, et al. Spectrum of phosphotidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009; 15: 6008-6017.
29. Onozato R, Kosaka T, Achiwa H, et al. LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci 2007; 11: 1747-1751.
30. Mhawech- Fauceglia P, Cheney RT, Schawaller J. Genetic alterations in urothelial bladder carcinoma. An updated review. Cancer 2006; 106: 1205-1216.
31. Cordon-Cardo C. Molecular alterations in bladder cancer. Cancer Surv 1998; 32: 115-131.
32. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphotidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009; 28: 305-316.
33. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA. AKT1 mutations in bladder cancer: Identification of a novel oncogenic mutation that co-operate with E17K. Oncogene 2010; 29: 150-155.
34. Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA. Bladder tumour derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum Mol Genet 2008; 17: 2006-2017.
35. Carpellen D, Diez G, deMedina S, Chopin D, Threy JP, Radvanyi F. Frequent loss of heterozygosity in chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997; 14: 3059-3066.
36. Kagan J, Liu J, Stein JD, et al. Cluster of allele loses within a 2.5cm region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 1998; 16: 909-913.
37. Kwiatkowski DJ. Rhebbing up mTOR: New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol Ther 2003; 2: 471-476.
38. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 2005; 15: 702-713.
39. Sarbassov DD, Ali SM, Sabatini DM. Growing roles form TOR pathway. Curr Opin Cell Biol 2005; 17: 596-603.
40. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signalling. Cancer Cell 2004; 6: 91-99.
41. Findlay GM, Harrington LS, Lamb RF. TSC1-2 tumour suppressor and regulation of mTOR signalling: Linking cell growth and proliferation? Curr Opin Genet Dev 2005; 15: 69-76.
42. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5: 578-581.
43. Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J Urol 2003; 170: 601-604.
44. Hezel AF, Gurumurthy S, Granot Z, et al. Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol 2008; 28: 2414-2425.
45. Shorning BY, Clarke AR. LKB1 loss of function studied in vivo. FEBS Lett 2011; 585: 958-966.
46. Rowan A, Bataille V, MacKie R, et al. Somatic mutations in the Peutz-Jeghers (LKB1/STK11) gene in sporadic malignant melanomas. J Invest Dermatol 1999; 112: 509-511.
47. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and billary cancers. Am J Pathol 1999; 154: 1835-1840.
48. Wingo SN, Gallardo TD, Akbay EA, et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE 2009; 4: e5137.
49. Avizienyte E, Roth S, Loukola A. Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res 1998; 58: 2087-2090.
50. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810.
51. Kenanli E, Karaman E, Enver O, Ulutin T, Buyru N. Genetic alterations of the LKB1 gene in head and neck cancer. DNA Cell Biol 2010; 29: 735-738.
52. Wang DS, Rieger-Christ K, Latini JM, et al. Molecular analysis of PTEN and MXI1 primary bladder carcinoma. Int J Cancer 2000; 88: 620-625.
53. Gromov PS, Madsen P, Tomerup N, Celis JE. A novel approach for expression cloning of small GTPases: Identification, tissue distribution and chromosome mapping of human homolog of Rheb. FEBS Lett 1995; 377: 221-226.